Manufacturing Speciality versus diversity: the four-way CDMO race in outsourced HPAPI manufacturing Pharmaceutical TechnologyGlobalData's Drugs By Manufacturer Database reveals the top four CDMOs for innovator and biosimilar HPAPI contract manufacturing.Read full story pharminent July 22, 2026 (Last updated: July 27, 2026) Pharmaceutical Technology GlobalData’s Drugs By Manufacturer Database reveals the top four CDMOs for innovator and biosimilar HPAPI contract manufacturing. Read full story Post navigation Previous: Samsung Biologics: geographic diversification is a sound business decisionNext: Arrowhead hits ‘best-case scenario’ with latest results for fat-lowering drug Related Stories Manufacturing Samsung Biologics inks $262M manufacturing deal with European pharma company pharminent September 11, 2026 Manufacturing Sandoz plans ‘vast and vertically integrated’ supply chain to support 100-biosimilar vision pharminent September 9, 2026 Manufacturing US puts $125m into personalised RNA therapy production pharminent September 2, 2026